2024 Is A Historic Year for Fatty Liver Disease. What’s Next?

On 14 March 2024, the U.S. Food and Drug Administration (FDA) approved the first treatment for noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise [1]. NASH is the more serious stage of non-alcoholic fatty liver disease (NAFLD), a silent killer affecting up to 40% of the population in Singapore [2].

From Bugs to Drugs: Harnessing the Power of Microbes as Living Medicines

The 1st BCS Biotech Writing Competition was held in 2023 where applicants submitted their entries on current biotechnology trends and opinions in Asia. In the wake of the COVID-19 pandemic and the perpetual outbreaks of Influenza, most of us see microbes as dangerous organisms. Our 3rd prize winner, Vanessa Lunardi, writes an informative piece that proves otherwise – maybe microbes can be used to benefit humankind after all.